Experimental approval of the application of bioflavonoid angioprotector for compensation of the influence ofhormonal contraceptives on parodont

Abstract

In the pathogenesis of periodontal diseases of women, an imbalance of sex hormones is important. It is considered as one of the provocative factors of periodontal disease. According to the literature, oral contraceptives may cause changes in periodontium similar to changes in puberty and pregnancy. For the correct choice of the method of treatment of these lesions, it was necessary to conduct an experimental investigation on animals. Aim. To determine the characteristics of the periodontal disease of women taking oral hormonal contraceptives for the purpose of planning pregnancy, determine the possible periodontoprotective effect of bioflavonoid angioprotector when using a hormonal contraceptive. Material and methods. A survey was conducted on 110 women, the main group was 80 women taking oral contraceptives, control 30 women who did not take them. To quantify the state of periodontal tissues, the Schiller-Pisarev test, the Green-Vermillion Hygiene Index, the Gingival Index (GI) by H. Loe, J. Silness, the Bleeding Index by H.R.Muhlemann, the index PMA by S. Parma, the index of the dental plaque of interdental gaps (API) by Lange. As a contraceptive used the drug "Yarina", containing ethinyl estradiol and drospirenone. As a bioflavonoid angioprotector, the drug Normoven was used, containing diosmin and hesperidin. Studies were performed on white female rats that received daily per os contraceptives at a dose of 2 μg / kg (ethinyl estradiol) and drospirenone at a dose of 200 μg / kg. The number of rats simultaneously received an angioprotector at a dose of 80 mg / kg (calculated on bioflavonoid). The duration of the experiment is 30 days. Blood cell count, biochemical parameters of blood serum and gums (urease, lysozyme, elastase, catalase, MDA), as well as periodontal bone tissue (phosphatase, calcium, protein) were determined. The degree of atrophy of the alveolar process was determined morphometrically. Results. The investigation showed that inflammatory and degenerative-inflammatory diseases of the periodontal tissue were detected in 78 (97.5%) women in the primary and in 28 (93.3%) women in the control group. They found an unsatisfactory state of oral hygiene in both groups. In 70 (89.7%) women in the primary group and 23 (82.1%) controls, chronic catarrhal gingivitis was detected; Generalized periodontitis was detected in 8 (11.3%) women in the primary group and in 5 (18.9%) women in the control group. Established with the introduction of a contraceptive development of inflammation in the gum, a decrease in the mineralizing activity of the bone (AP / CF) and an increase in the degree of atrophy of the alveolar process. Simultaneous introduction of an angioprotector stimulates mineralizing activity and reduces the degree of atrophy of the alveolar process bone. Conclusions Analysis of the data shows a significant level of inflammatory and dystrophic-inflammatory periodontal disease in the examined women. Attention is drawn to a somewhat lesser extent of their prevalence in women taking contraceptives. Bioflavonoid angioprotector "Normoven" has a periodontoprotective effect when using a hormonal contraceptive